WO2009076602A8 - 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors - Google Patents

5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors Download PDF

Info

Publication number
WO2009076602A8
WO2009076602A8 PCT/US2008/086594 US2008086594W WO2009076602A8 WO 2009076602 A8 WO2009076602 A8 WO 2009076602A8 US 2008086594 W US2008086594 W US 2008086594W WO 2009076602 A8 WO2009076602 A8 WO 2009076602A8
Authority
WO
WIPO (PCT)
Prior art keywords
cyanopyridines
alkenyl
alkyl
kinase inhibitors
compounds
Prior art date
Application number
PCT/US2008/086594
Other languages
French (fr)
Other versions
WO2009076602A1 (en
Inventor
Lawrence Nathan Tumey
Diane Harris Boschelli
Niala Bhagirath
Joan Jowen Chen
Middleton Brawner Floyd, Jr.
Zhong Li
Chuansheng Niu
Jaechul Shim
Yan Wang
Yanong Daniel Wang
Biqi Wu
Clark N. Eid, Jr.
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Priority to CA2709314A priority Critical patent/CA2709314A1/en
Priority to EP08859530A priority patent/EP2229377A1/en
Priority to JP2010538186A priority patent/JP2011506475A/en
Publication of WO2009076602A1 publication Critical patent/WO2009076602A1/en
Publication of WO2009076602A8 publication Critical patent/WO2009076602A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Described herein are compounds of formula I: wherein G is and pharmaceutically acceptable salts thereof, wherein J, X, R1, R2, R11, R12' and p are as defined herein. Also provided herein are methods of making the compounds of formula I, and methods of using these compounds for inhibiting or treating a pathological condition or disorder linked to or mediated by a protein kinase in a mammal.
PCT/US2008/086594 2007-12-13 2008-12-12 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors WO2009076602A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2709314A CA2709314A1 (en) 2007-12-13 2008-12-12 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors
EP08859530A EP2229377A1 (en) 2007-12-13 2008-12-12 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors
JP2010538186A JP2011506475A (en) 2007-12-13 2008-12-12 5-Alkyl / alkenyl-3-cyanopyridines as kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1345707P 2007-12-13 2007-12-13
US61/013,457 2007-12-13

Publications (2)

Publication Number Publication Date
WO2009076602A1 WO2009076602A1 (en) 2009-06-18
WO2009076602A8 true WO2009076602A8 (en) 2010-02-18

Family

ID=40429261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/086594 WO2009076602A1 (en) 2007-12-13 2008-12-12 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors

Country Status (5)

Country Link
EP (1) EP2229377A1 (en)
JP (1) JP2011506475A (en)
CA (1) CA2709314A1 (en)
CL (1) CL2008003675A1 (en)
WO (1) WO2009076602A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101452579B1 (en) * 2012-08-17 2014-10-21 주식회사 두산 Novel compound and organic electroluminescent device comprising the same
AR094812A1 (en) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
KR102344105B1 (en) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 Salt of monocyclic pyridine derivative and crystal thereof
WO2017013593A1 (en) 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
AU2019241625A1 (en) 2018-03-28 2020-09-03 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781591B2 (en) * 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
JP2008540656A (en) * 2005-05-18 2008-11-20 ワイス 3-cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same

Also Published As

Publication number Publication date
WO2009076602A1 (en) 2009-06-18
CA2709314A1 (en) 2009-06-18
EP2229377A1 (en) 2010-09-22
JP2011506475A (en) 2011-03-03
CL2008003675A1 (en) 2009-03-20

Similar Documents

Publication Publication Date Title
NL300929I2 (en) Telotristat, optionally in the form of a pharmaceutically acceptable ester or salt, in particular telotristat ethyl, more in particular the hippurate salt of telotristat ethyl
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
WO2013053983A8 (en) Protein kinase inhibitors
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
UA99361C2 (en) TRIAZINE COMPOUNDS AS PI3 KINASE AND mTOR INHIBITORS
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
WO2008137816A3 (en) Tricyclic compounds as matrix metalloproteinase inhibitors
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
MX2010006799A (en) Benzofuropyrimidinones as protein kinase inhibitors.
EP2090577A3 (en) Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2011123946A8 (en) Kinase inhibitors and method of treating cancer with same
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
MX2009011579A (en) Pyrimidinones as casein kinase ii (ck2) modulators.
EA200802329A1 (en) TRIAZOLE DERIVATIVES II
WO2009091898A3 (en) 6-and 7-amino isoquinoline compounds and methods for making and using the same
WO2006116733A3 (en) Protein kinase inhibitors
WO2008086122A3 (en) Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859530

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010538186

Country of ref document: JP

Ref document number: 2709314

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008859530

Country of ref document: EP